

Medicines Patent Pool Governance Board Meeting #26

April 28, 2020
held virtually due to Covid-19

Attendees

Governance Board Members:

Dr Marie-Paule Kieny, Dr Charles Clift, Dr Manica Balasegaram, Mr Mohammed Barry, Dr Patrizia Carlevaro, Dr Claudia Chamas and Ms Jayashree Watal.

Non-voting members:

Mr Maximiliano Santa Cruz*, Dr Mariângela Batista Galvão Simão - WHO observer*, Mr Jan Akko Eleveld – Unitaid Project Team, Mr Robert Matiru – Unitaid Executive Team and Dr Luis Pizarro de Trenquallye – Unitaid Executive Team.

Medicines Patent Pool Foundation Staff Members:


Charles Gore – Executive Director, Karine Belondrade – Head of Strategy, Operations and Resource Mobilisation, Esteban Burrone – Head of Policy, Vincent Chauvin – CFO, Head of Human Resources, Gelise McCullough – Head of Communications, Sandra Nobre – Head of Business Development, Chan Park – General Counsel, Lobna Gaayeb – Long Acting Technologies Project Manager and Vivian Ntinyari – Grants and Operations Manager (rapporteur).

**These individuals attended part of the Board meeting only*

Summary of Decisions

The Governance Board of the Medicines Patent Pool:

1. Approves and adopts the minutes of Governance Board meeting #25 held on October 14-15, 2019 and approves the agenda of the Governance Board Meeting #26.
2. In the context of quality assurance, approves the implementing option 2: “Strengthen the monitoring of regulatory status and reporting obligations; Publish regulatory statuses and updates on MPP’s website to allow purchasers to do verification at reception; and, Explore the possibility of asking manufacturers for specification and process information if a situation arises where quality control is needed reactively after a problem is detected on a particular product”.



3. In the context of the long-acting technologies exploratory phase, approves to move forward with the process of putting candidate products through the decision tree. The Board further requests that the scope of work related to long-acting technologies be discussed at the October 2020 Board meeting. This should include an update on any significant changes made to the decision tree.
4. Approves the 2019 annual report of activities; the 2019 financial statements and the auditors' report; and the risk assessment report.
5. Approves the proposed Board Diversity Policy.